Brokerages Expect OPKO Health, Inc. (NASDAQ:OPK) Will Announce Quarterly Sales of $304.07 Million

Equities research analysts expect that OPKO Health, Inc. (NASDAQ:OPK) will announce $304.07 million in sales for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for OPKO Health’s earnings, with estimates ranging from $298.60 million to $307.10 million. OPKO Health posted sales of $428.10 million during the same quarter last year, which suggests a negative year-over-year growth rate of 29%. The business is scheduled to issue its next quarterly earnings results on Thursday, November 4th.

According to Zacks, analysts expect that OPKO Health will report full-year sales of $1.58 billion for the current financial year, with estimates ranging from $1.54 billion to $1.61 billion. For the next fiscal year, analysts expect that the business will report sales of $1.31 billion, with estimates ranging from $1.16 billion to $1.44 billion. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for OPKO Health.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings results on Thursday, July 29th. The biotechnology company reported ($0.03) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.05). OPKO Health had a net margin of 3.71% and a return on equity of 4.21%. The business had revenue of $442.40 million for the quarter, compared to analyst estimates of $457.57 million.

Several research firms recently weighed in on OPK. LADENBURG THALM/SH SH initiated coverage on shares of OPKO Health in a report on Monday, June 21st. They issued a “buy” rating and a $7.00 price objective for the company. Barrington Research restated a “buy” rating and issued a $6.00 price objective on shares of OPKO Health in a report on Monday, September 27th. Finally, Piper Sandler reaffirmed a “buy” rating and set a $5.00 target price on shares of OPKO Health in a research report on Friday, September 24th.

In other news, CEO Phillip Md Et Al Frost acquired 100,000 shares of the business’s stock in a transaction on Tuesday, September 14th. The shares were acquired at an average cost of $3.46 per share, with a total value of $346,000.00. Following the transaction, the chief executive officer now owns 3,068,951 shares in the company, valued at approximately $10,618,570.46. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 41.47% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Quantbot Technologies LP increased its position in shares of OPKO Health by 129.9% in the 1st quarter. Quantbot Technologies LP now owns 7,294 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 4,122 shares during the last quarter. Eqis Capital Management Inc. acquired a new stake in shares of OPKO Health in the second quarter worth approximately $41,000. Virtu Financial LLC acquired a new position in OPKO Health during the first quarter valued at approximately $48,000. Profund Advisors LLC acquired a new position in shares of OPKO Health during the first quarter worth $52,000. Finally, Beacon Pointe Advisors LLC bought a new stake in shares of OPKO Health in the second quarter worth $51,000. Institutional investors own 27.56% of the company’s stock.

OPK stock traded up $0.07 during trading on Monday, hitting $3.80. 52,583 shares of the company’s stock traded hands, compared to its average volume of 5,145,085. The company has a quick ratio of 1.36, a current ratio of 1.80 and a debt-to-equity ratio of 0.11. OPKO Health has a 52 week low of $3.02 and a 52 week high of $6.27. The stock has a fifty day moving average price of $3.72 and a two-hundred day moving average price of $3.83. The stock has a market capitalization of $2.59 billion, a price-to-earnings ratio of 34.46 and a beta of 1.75.

About OPKO Health

OPKO Health, Inc, is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment include clinical laboratory operations of BioReference, as well as point-of-care operations.

Recommended Story: How do buyers and sellers choose a strike price?

Get a free copy of the Zacks research report on OPKO Health (OPK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for OPKO Health (NASDAQ:OPK)

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.